Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2018

View Archived Issues

HM-81422 as a novel treatment option for patients with HCC with altered FGF19/FGFR4 pathway

Novel BET bromodomain inhibitor TG-1601 a clinical candidate

Bill & Melinda Gates Foundation grant supports Recursion's expansion into malaria

Procella and Smartwise establish cardiovascular collaboration with AstraZeneca

Novel formulation of ribaxamase protects the gut microbiome

Delcath initiates pivotal trial of melphalan in intrahepatic cholangiocarcinoma

Secarna Pharmaceuticals patents novel anti-CD39 immunosuppression-reverting oligonucleotides

EMA gives positive scientific advice on development plan and regulatory pathway for AM-111

CARB-X supports Melinta's development of pyrrolocytosine compounds

Human papillomavirus cancer vaccine utilizes CD11b-targeting nanobodies

Pfizer nominates final hepatic targets under collaboration with Wave Life Sciences

E.U. funding supports development of The Cell Factory's second-generation EV drug for stroke

FDA approves Darzalex with VMP for newly diagnosed multiple myeloma

QuANTUM-R study of quizartinib in FLT3-ITD-mutated AML meets primary endpoint

FDA approves Myrbetriq in combination with solifenacin for overactive bladder

Aptose exercises option to license CrystalGenomics' CG-806

New trial explores use of AMO-01 in Phelan-McDermid syndrome

Takeda and Shire reach agreement on recommended offer for Shire

INTEREST study of Traumakine in ARDS does not meet primary efficacy composite endpoint

Polaris Pharmaceuticals creates new ADI-TRAIL fusion protein with antitumor activity

Carna collaborates with Evotec to accelerate development of CB-1763

FDA grants fast track designation to Debio-1347

Valeant Pharmaceuticals International to change name to Bausch Health Companies